Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
about
Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis.LPA receptor signaling: pharmacology, physiology, and pathophysiology.Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.Activation of Lysophosphatidic Acid Receptor Type 1 Contributes to Pathophysiology of Spinal Cord InjuryInsights into the pharmacological relevance of lysophospholipid receptors.The lysophosphatidic acid receptor LPA1 promotes epithelial cell apoptosis after lung injuryIdentification of Intrinsic Axon Growth Modulators for Intact CNS Neurons after Injury.Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions.LPA1-induced cytoskeleton reorganization drives fibrosis through CTGF-dependent fibroblast proliferation.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures PerspectivesIntercellular Lipid Mediators and GPCR Drug DiscoveryLysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase.Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts.Action and Signaling of Lysophosphatidylethanolamine in MDA-MB-231 Breast Cancer Cells.Calcium Signaling of Lysophosphatidylethanolamine through LPA1 in Human SH-SY5Y Neuroblastoma Cells.Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.Design of anticancer lysophosphatidic acid agonists and antagonists.New renal drug development to face chronic renal disease.Promising pharmacological directions in the world of lysophosphatidic Acid signaling.Novel Drug Targets For Idiopathic Pulmonary Fibrosis.Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.Lysophosphatidic acid (LPA) as a pro-fibrotic and pro-oncogenic factor: a pivotal target to improve the radiotherapy therapeutic index.Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis.Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis
P2860
Q33756825-7B34A956-BBAE-40CE-A219-75EEA903849DQ33825153-2939B3D4-8F11-49BF-BEB7-9A1593F57339Q35551835-2FBBF0A6-B916-40E5-B595-053D368D142EQ35851510-D6570FEE-394E-4C10-B348-125A204F8967Q35853199-97A626A3-6B57-46AE-B24C-BD05DF55937AQ35889195-DEDEEE72-35DA-42BD-9670-0D442A14EEA8Q36309440-1C2DD116-A123-4D25-A957-77C48CCDF368Q36412800-A6395FBF-DF99-4E68-B55D-0F13966D3566Q36788697-2C270451-785D-4419-9B52-B804675B5B7FQ37381549-E85EEA1C-12DD-4924-BBCD-95399AEED515Q37429742-42D87CC0-327A-4FB1-95EC-D33779C0C53BQ37503698-5C76EDA6-7AE8-435B-AE5A-504F1197B2C7Q37562363-8A5F9F47-47AF-4AEA-BDFF-E3833F742D46Q37684220-767528A3-B350-4A52-95EB-A5FD73F7A468Q37685105-CE975EA0-6CBB-4822-B046-AB40BB39E911Q37730679-926E8638-2EA8-46F9-931E-BDBF6E5C497BQ38223013-E74C14C6-F494-4597-869E-7F08A1FB23DCQ38246640-3A2C9724-D12B-4580-A832-AFAA7FCB0D41Q38320338-159FF00D-2A11-4880-842F-516F735F8CF7Q38725808-DCCD7384-0089-4DA0-9132-50119CA913E2Q38726399-C2AFCF38-8EBC-47C7-8428-761B556A37F1Q39237720-54EE90E9-0DFB-4FDE-8926-B494F3BD21E6Q39277013-DD510A73-FBC8-4486-8A0E-F8C202AAF1B7Q42761894-87346BE0-849C-4A89-9634-411E4FBE4A07
P2860
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetic and pharmacody ...... receptor-selective antagonist.
@en
Pharmacokinetic and pharmacody ...... receptor-selective antagonist.
@nl
type
label
Pharmacokinetic and pharmacody ...... receptor-selective antagonist.
@en
Pharmacokinetic and pharmacody ...... receptor-selective antagonist.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... receptor-selective antagonist.
@en
Pharmacokinetic and pharmacody ...... receptor-selective antagonist.
@nl
P2093
P356
P1476
Pharmacokinetic and pharmacody ...... receptor-selective antagonist.
@en
P2093
A M Santini
A R Broadhead
C S Baccei
D S Lorrain
J Darlington
P304
P356
10.1124/JPET.110.175901
P407
P577
2010-12-15T00:00:00Z